Health Technology Assessments Should Help Prioritize CER – Journal Authors
While health technology assessment’s role primarily is to aid clinical and policy decision-making, it also has the potential to help prioritize the comparative effectiveness research agenda as well as inform trial designs, according to a recent article in the Journal of Clinical Oncology.
You may also be interested in...
Several articles in a comparative effectiveness research-themed issue of the Journal of Clinical Oncology highlight the need for CER to use common language and data collection standards to boost the value and usefulness of the research.
Pharma companies’ comparative effectiveness research should be “in sync” with nationalized approach that the Patient-Centered Outcomes Research Institute will bring, Clyde Yancy, member of the new institute’s Methodology Committee, suggests.
Evidence within compendia to support the off-label use of targeted cancer therapies varies widely and is rapidly evolving, making it difficult to draw solid conclusions regarding safety and efficacy, according to a draft technology assessment report released for comment by the Agency for Healthcare Research and Quality